Key Takeaways Shares of Viking Therapeutics surged Wednesday after J.P. Morgan analysts initiated coverage of the drugmaker at "overweight" and shared an optimistic view. Viking is developing weight-loss drugs that have boosted its stock after positive trial results since the start of this year, and analysts say it might happen again. In the long term, analysts predict that Viking's anticipated oral weight-loss drug could claim about 10% of the market in the years following its projected 2030 release. Vikin ...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc VKTX with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65. At the core of this bullish outlook is Viking's obesity drug candidate, oral-2735, which could be a significant player in the rapidly expanding GLP-1 market. Oral-2735 Could Be A Game Changer JPMorgan highlights oral-2735's potential as a highly competitive treatment in the GLP-1 market, par ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $54.78, denoting a +1.2% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 1.16%. Elsewhere, the Dow gained 1.2%, while the tech-heavy Nasdaq added 1.16%. The company's stock has dropped by 5.3% in the past month, falling short of the Medical sector's gain of 4.5% and the S&P 500's gain of 3.48%. The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The co ...

The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock. Wall Street investment banks keep pounding the table on Viking Therapeutics (VKTX -2.27%) and its weight loss drug candidate. Predictions vary, but the average analyst who follows the stock thinks it can rise 98% from recent prices. Investment bank analysts aren't the only folks on Wall Street who think the clinical-stage biopharma has a bright future. In the second quarter, billionaire mone ...

Nvidia is heading for a 118% gain this year. Nvidia (NVDA -1.66%) is a tough one to beat when it comes to share-price performance. The technology giant has seen its shares soar 2,500% over the past five years, and this year, it's heading for a 118% increase. There's a good reason for this incredible run. Nvidia dominates one of today's biggest growth areas -- the artificial intelligence (AI) chip market -- holding an 80% share. As a result, Nvidia's earnings have been climbing in the triple digits to new re ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $58.10, moving -0.5% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.16%. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, lost 0.3%. Coming into today, shares of the company had gained 9.49% in the past month. In that same time, the Medical sector gained 4.7%, while the S&P 500 gained 3.64%. The investment community will be paying close attention to the earnings pe ...

Shares of Viking Therapeutics (VKTX) have more than tripled in market value in the past year. The upside was triggered by positive updates on its pipeline programs for obesity and non-alcoholic steatohepatitis (NASH) indications. Based on the encouraging results, management intends to meet with the FDA to discuss the late-stage study design and timings for both programs. In the past year, the stock has significantly outperformed the industry's 2.5% decline. The stock has outperformed the sector and the S&P ...

This business has solid results in hand, lots of cash, and more catalysts coming. In biotech, sometimes it's the companies that aren't making a single dime that end up being the very best investments after a short time. For instance, Viking Therapeutics (VKTX -1.54%) doesn't yet have any revenue. But thanks to its ongoing clinical investigations and the high-quality data they're yielding, Viking shares have vaulted 347% in the last 12 months alone. And that might just be the start. So if you're looking to m ...

Shares of Viking Therapeutics (VKTX) fell 6% on Tuesday after pharma giant Eli Lilly (LLY) announced the launch of single-dose vials of its popular obesity drug, Zepbound (tirzepatide). These new vials are priced at least 50% lower than the list price of competing GLP-1 medicines for obesity. A four-week supply of the 2.5 mg vials has been priced at $399 while the same for the 5 mg dose will cost $549. Zepbound is available in a single-dose pen (autoinjector), which is priced at about $1,000 for a month's s ...

A monster rival is making aggressive moves in one particular segment. News from a deep-pocketed rival put the hurt on biotech Viking Therapeutics's (VKTX -6.27%) stock on Tuesday. Said rival seems determined to dominate a very hot therapeutic area these days, and it might be tough for a relatively small fry like Viking to compete. On the back of such worries, investors sold out of the biotech, sending its share price down by more than 6% across the trading session. That was on a good day for stocks, general ...